With Low Percentage Of R&D Funding Going Toward NTDs, Some Pharmaceutical Companies Focus On Partnerships, Collaboration

The Guardian: Is it fair to accuse the pharma industry of neglecting tropical diseases?
“…Currently the biggest impetus for dealing with NTDs seems to come from partnerships. … There is some evidence to suggest the pharma industry uses partnerships to absolve itself of responsibility. Major companies are closing down their NTD R&D operations while opening up their compound libraries to partnerships, such as Novartis to the TB Alliance. … The solution for NTD drug R&D may not be partnerships alone, but must include cross-sector collaboration…” (Smedley, 10/15).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.